论文部分内容阅读
:8 0年代 ,全球几家生物技术公司开展多种转基因动物乳腺生产人蛋白质类治疗药物的先驱性研制工作 ,其中采用这种途径生产的人抗凝血因子Ⅲ和α 1-抗胰蛋白酶已于 1990年底通过临床实验 ,成为全球首批转基因生产的蛋白质类药物 ,该生产计划已被医药权威机构认可并将在2 0 0 0年左右投放市场。尽管在生物制药上取得了重大进展 ,但胚胎基础研究和应用推广人员仍面临其它一些转基因问题的巨大挑战。同时生物制药业认为还需通过另外一些新技术 (如克隆、精子性别鉴定和反转录病毒介导的基因转移等 )来克服自然生物学上的屏障 ,以增加转基因奶类动物的生产效率并快速扩大生产群
: In the 1980s, several biotechnology companies worldwide pioneered the development of protein therapeutics for a variety of transgenic animal mammary glands, of which human anti-coagulation factor III and α 1 -antitrypsin have been produced By the end of 1990 through clinical trials, becoming the world’s first GM genetically modified protein drugs, the production plan has been recognized by the pharmaceutical authorities and will be put on the market around 2000. Despite significant advances in biopharmaceuticals, basic research and extension practitioners of embryos are still faced with a number of other significant genetic and genetic challenges. At the same time, the biopharmaceutical industry believes that it is necessary to overcome natural biological barriers through other new technologies (such as cloning, sperm sex identification and retrovirus-mediated gene transfer) to increase the production efficiency of transgenic dairy animals Rapid expansion of the production base